Skip to content

Study · Observational study · n = 62 · 2024

6 results

Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.

Duong A, Heacock S, Amering S, Brennan L, Venci J, Acquisto NM

The Annals of pharmacotherapy24 Sept 2023

PMID37743669 (opens in a new tab)DOI10.1177/10600280231199852 (opens in a new tab)PepBankPUB-37743669
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with T2DM, dulaglutide was linked to a mean weight decrease of 1.8 kg from baseline.

    In plain wordsIn adults with T2DM, dulaglutide was linked to lower weight than at baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight change with lower dose
    Study

    n = 62

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg weekly · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −1.8 kg
    3 mg at 24 weeks

    Source sentences

    Summary
    After 24 weeks, the mean changes in weight and HbA1c from baseline were -1.8 kg (P P P P = 0.119) in the 4.5 mg group.
    2 context sentences
    Summary · context
    Ninety-five patients were included, 62 in the dulaglutide 3 mg group and 33 in the dulaglutide 4.5 mg group.
    Summary · context
    Retrospective, observational study of adult T2DM patients receiving dulaglutide 3 or 4.5 mg weekly within a large, university-affiliated, primary care network.
  2. 02HumanObservational studyEfficacy outcome

    In adults with T2DM, dulaglutide was linked to a mean HbA1c decrease of 0.4% from baseline.

    In plain wordsIn adults with T2DM, dulaglutide was linked to lower HbA1c than at baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change with lower dose
    Study

    n = 62

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3 mg weekly · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.4%
    3 mg at 24 weeks

    Source sentences

    Summary
    After 24 weeks, the mean changes in weight and HbA1c from baseline were -1.8 kg (P P P P = 0.119) in the 4.5 mg group.
    2 context sentences
    Summary · context
    Ninety-five patients were included, 62 in the dulaglutide 3 mg group and 33 in the dulaglutide 4.5 mg group.
    Summary · context
    Retrospective, observational study of adult T2DM patients receiving dulaglutide 3 or 4.5 mg weekly within a large, university-affiliated, primary care network.
  3. 03HumanObservational studyEfficacy outcome

    In adults with T2DM, dulaglutide was linked to a mean weight decrease of 4.2 kg from baseline.

    In plain wordsIn adults with T2DM, dulaglutide was linked to lower weight than at baseline.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight change with higher dose
    Study

    n = 33

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    4.5 mg weekly · 24 weeksAs given in this study (human).

    Measurements

    Weight change
    −4.2 kg
    4.5 mg at 24 weeks

    Source sentences

    Summary
    After 24 weeks, the mean changes in weight and HbA1c from baseline were -1.8 kg (P P P P = 0.119) in the 4.5 mg group.
    2 context sentences
    Summary · context
    Ninety-five patients were included, 62 in the dulaglutide 3 mg group and 33 in the dulaglutide 4.5 mg group.
    Summary · context
    Retrospective, observational study of adult T2DM patients receiving dulaglutide 3 or 4.5 mg weekly within a large, university-affiliated, primary care network.
  4. 04HumanObservational studyEfficacy outcome

    In adults with T2DM, the mean HbA1c decrease with dulaglutide from baseline was not statistically significant.

    In plain wordsIn adults with T2DM, HbA1c did not change significantly from baseline during dulaglutide treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeHbA1c change with higher dose
    Study

    n = 33

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    4.5 mg weekly · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.4%
    4.5 mg at 24 weeks

    Source sentences

    Summary
    After 24 weeks, the mean changes in weight and HbA1c from baseline were -1.8 kg (P P P P = 0.119) in the 4.5 mg group.
    2 context sentences
    Summary · context
    Ninety-five patients were included, 62 in the dulaglutide 3 mg group and 33 in the dulaglutide 4.5 mg group.
    Summary · context
    Retrospective, observational study of adult T2DM patients receiving dulaglutide 3 or 4.5 mg weekly within a large, university-affiliated, primary care network.
  5. 05HumanObservational studyEfficacy outcome

    In adults with T2DM, dulaglutide titration was linked to an incremental weight decrease of 2.6 kg.

    In plain wordsIn adults with T2DM, dulaglutide dose titration was linked to lower weight than before titration.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseIncremental weight change after titration
    Study

    n: not reported in source

    Comparator
    Before titration from 3 to 4.5 mg weekly
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Titration from 3 to 4.5 mg weeklyAs given in this study (human).

    Measurements

    Incremental weight change
    −2.6 kg
    Titration from 3 to 4.5 mg weekly

    Source sentences

    Summary
    Incremental change in weight and HbA1c among patients who were titrated from dulaglutide 3 to 4.5 mg weekly were -2.6 kg (P P = 0.04), respectively.
    1 context sentence
    Summary · context
    Retrospective, observational study of adult T2DM patients receiving dulaglutide 3 or 4.5 mg weekly within a large, university-affiliated, primary care network.
  6. 06HumanObservational studyEfficacy outcome

    In adults with T2DM, dulaglutide titration was linked to an incremental HbA1c decrease of 0.2%.

    In plain wordsIn adults with T2DM, dulaglutide dose titration was linked to lower HbA1c than before titration.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseIncremental HbA1c change after titration
    Study

    n: not reported in source

    Comparator
    Before titration from 3 to 4.5 mg weekly
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Titration from 3 to 4.5 mg weeklyAs given in this study (human).

    Measurements

    Incremental HbA1c change
    −0.2%
    Titration from 3 to 4.5 mg weekly

    Source sentences

    Summary
    Incremental change in weight and HbA1c among patients who were titrated from dulaglutide 3 to 4.5 mg weekly were -2.6 kg (P P = 0.04), respectively.
    1 context sentence
    Summary · context
    Retrospective, observational study of adult T2DM patients receiving dulaglutide 3 or 4.5 mg weekly within a large, university-affiliated, primary care network.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.